



Victoza® (liraglutide) – First-time authorized brand alternative

- On June 24, 2024, [Teva launched](#) an authorized brand alternative of Novo Nordisk's [Victoza \(liraglutide\)](#) injection.
- Victoza is approved for the following:
 - An adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus (T2DM)
 - To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with T2DM and established CV disease.
- Victoza carries a boxed warning for risk of thyroid C-cell tumor.
- The wholesale acquisition cost (WAC) for Teva's Victoza authorized brand alternative is \$469.60 for the 2-pen package and \$704.40 for the 3-pen package. This is ~13.5% lower cost than brand Victoza.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.